The efficacy and safety of adding tocilizumab to methotrexate and intra-articular glucocorticosteroid treatment in early rheumatoid arthritis. A randomized, double-blinded, placebo-controlled trial.
Read time: 1 mins
Last updated:25th May 2012
In a multicentre, randomized, two-armed, parallel group, double-blind design in patients with early rheumatoid arthritis to investigate whether it is possible by adding tocilizumab to achieve: 1. Inflammatory control as assessed by number of patients who achieve remission (DAS28<2.6) after 12 months of and 2. sustained remission (das28>< 2.6 for 6 consecutive months) after 12 months of treatment and 3. Radiological control assessed by number of patients without radiological progression of the hands/wrists and upper feet from baseline to 12 months of treatment (Increase in total Sharp score (TSS), joint spacing narrowing (JSN) or joint erosions (JE) > 0.5 units)
|Study start date||2012-05-25|